<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>The <z:hpo ids='HP_0002667'>Wilms tumor</z:hpo> gene, WT1, is overexpressed not only in <z:hpo ids='HP_0001909'>leukemias</z:hpo> and <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) but also in various types of <z:e sem="disease" ids="C0280100" disease_type="Neoplastic Process" abbrv="">solid tumors</z:e>, including lung and <z:hpo ids='HP_0003002'>breast cancer</z:hpo>, and the WT1 protein is a <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> antigen for these <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>In clinical trials of WT1 <z:chebi fb="7" ids="16670">peptide</z:chebi>-based <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> immunotherapy, patients with overt <z:hpo ids='HP_0001909'>leukemia</z:hpo> from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> with <z:hpo ids='HP_0011974'>myelofibrosis</z:hpo> were injected intradermally with 0.3 mg of an HLA-A*2402-restricted, 9-mer WT1 <z:chebi fb="7" ids="16670">peptide</z:chebi> emulsified with Montanide ISA51 adjuvant </plain></SENT>
<SENT sid="2" pm="."><plain>Only a single dose of WT1 vaccination resulted in an increase in WT1-specific cytotoxic T-lymphocytes, which was followed by a rapid reduction in leukemic blast cells </plain></SENT>
<SENT sid="3" pm="."><plain>Severe <z:hpo ids='HP_0001882'>leukopenia</z:hpo> and local <z:hpo ids='HP_0010783'>erythema</z:hpo> at the injection sites of WT1 <z:chebi fb="7" ids="16670">peptide</z:chebi> were observed as adverse effects </plain></SENT>
<SENT sid="4" pm="."><plain>These results have provided us with the first clinical evidence suggesting that WT1 <z:chebi fb="7" ids="16670">peptide</z:chebi>-based immunotherapy is an attractive treatment for patients with <z:hpo ids='HP_0001909'>leukemias</z:hpo> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
</text></document>